Bamlanivimab and etesevimab for COVID-19
Active substance: bamlanivimab, Etesevimab
bamlanivimab, Etesevimab
Centralised EU authorisationActive
Marketing holder: Eli Lilly Nederland B.V.
Verified 2026-10-09 · EMA
- Source: EMA
- Countries with the substance registered: 1
Composition
Registration
- Registration number
- EMEA/H/C/005836
- Registration status
- Active
Sources
- product · EMA · EMEA/H/C/005836 · Verified 2026-10-09
- registration_status · EMA · EMEA/H/C/005836 · Verified 2026-10-09
- ingredients.0 · EMA · EMEA/H/C/005836 · Verified 2026-10-09
- ingredients.1 · EMA · EMEA/H/C/005836 · Verified 2026-10-09